AGREEMENT AND PLAN OF MERGER dated as of April 26, 2017 by and among Eagle Holding Company I Eagle Holding Company II, LLC EAGLE REORGANIZATION MERGER SUB, INC. EAGLE BUYER, INC. and JAGUAR HOLDING COMPANY IMerger Agreement • February 26th, 2021 • PPD, Inc. • Services-commercial physical & biological research • Delaware
This Agreement and Plan of Merger (this “Agreement”), dated as of April 26, 2017, is entered into by and among Eagle Holding Company I, a Delaware corporation (“Parent”), Eagle Holding Company II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Holdings”), Eagle Reorganization Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Holdings (“Merger Sub”), Eagle Buyer, Inc., a Delaware corporation (“Buyer”), and Jaguar Holding Company I, a Delaware corporation (together with its successors and assigns, the “Company”).
EAGLE HOLDING COMPANY I WILMINGTON, NORTH CAROLINA 28401 May 11, 2017Stockholders Agreement • February 26th, 2021 • PPD, Inc. • Services-commercial physical & biological research
Reference is made to (i) the Stockholders Agreement, dated as of May 11, 2017 (the "Stockholders Agreement"), by and among Eagle Holding Company I, a Delaware corporation (together with any successor, the "Company"), Carlyle Partners VI Holdings II, L.P., a Delaware limited partnership, Carlyle Partners VI, L.P., a Delaware limited partnership, CP VI Coinvestment A, L.P., a Delaware limited partnership, CP VI Coinvestment B, L.P., a Delaware limited partnership, Hellman & Friedman Capital Partners VII, L.P., a Cayman Islands limited partnership, Hellman & Friedman Capital Partners VII (Parallel), L.P., a Cayman Islands limited partnership, HFCP VII (Parallel-A), L.P., a Delaware limited partnership, and H&F Executives VII, L.P., a Cayman Islands limited partnership, Hellman & Friedman Capital Partners VIII, L.P., a Cayman Islands limited partnership, Hellman & Friedman Capital Partners VIII (Parallel), L.P., a Cayman Islands limited partnership, HFCP VIII (Parallel-A), L.P., a Delaware
EMPLOYMENT AGREEMENTEmployment Agreement • February 26th, 2021 • PPD, Inc. • Services-commercial physical & biological research • North Carolina
This Employment Agreement (this "Agreement"), dated as of the 22nd day of May, 2013 (the "Effective Date"), is made by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (together with any successor thereto, the "Company"), and David Johnston (the "Executive" and, together with the Company, the "Parties") and, solely with respect to Section 9(n), Jaguar Holding Company I, a Delaware corporation ("Parent").
ASSIGNMENT AND ASSUMPTION AGREEMENTAssignment and Assumption Agreement • February 26th, 2021 • PPD, Inc. • Services-commercial physical & biological research • North Carolina
THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this "Agreement"), dated as of May 11, 2017, is entered into by and among Jaguar Holding Company I, a Delaware corporation (the "Assignor"), Eagle Holding Company I, a Delaware corporation (the "Assignee"), Pharmaceutical Product Development, LLC, a Delaware limited liability company ("PPD") and David M. Johnston (the "Executive"). Capitalized or other terms used and not defined herein shall have the meanings ascribed to them in that certain Agreement and Plan of Merger, dated as of April 26, 2017 (as amended, restated, modified or supplemented from time to time, the "Merger Agreement"), by and among the Assignee, Eagle Holding Company II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Assignee ("Holdings"), Eagle Reorganization Merger Sub, Inc., a Delaware corporation and wholly- owned subsidiary of Holdings, Eagle Buyer, Inc., a Delaware corporation and the Assignor.
AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENTEmployment Agreement • February 26th, 2021 • PPD, Inc. • Services-commercial physical & biological research
THIS AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT (the “Amendment No. 3”), made and entered into this 23 day of February, 2021 and shall be effective as of February 1, 2021 (the “Effective Date”), by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (the “Company”), and David M. Johnston (the “Executive”).
AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENTEmployment Agreement • February 26th, 2021 • PPD, Inc. • Services-commercial physical & biological research
THIS AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT (the “Amendment No. 2”), made and entered into this 1st day of April, 2018 (the “Effective Date”) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the “Company”), and David M. Johnston (the “Executive”).
AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 26th, 2021 • PPD, Inc. • Services-commercial physical & biological research
THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Amendment No. 1”), made and entered into this 23 day of February, 2021 and shall be effective as of February 1, 2021 (the “Effective Date”), by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (the “Company”), and Anshul Thakral (the “Executive”).
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • February 26th, 2021 • PPD, Inc. • Services-commercial physical & biological research
THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (the "Amendment No. 1”), made and entered into this 15th day of December, 2016, effective as of the 1st day of December, 2016 (the "Effective Date”), by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (the "Company"), and David Johnston (the "Executive").
